MCO-010, an optogenetic therapy, demonstrated long-term safety and improved quality of life in patients with retinitis pigmentosa after a single intravitreal injection, according to a press release from Nanoscope Therapeutics.
“Patients with RP suffer from a progressive decline in vision following the natural course of disease progression, with no treatment available to halt or even slow the deterioration,” Samarendra Mohanty, PhD, president, chief scientific officer and cofounder of Nanoscope, told Healio. “The durable safety and improved patient-reported outcomes observed in the EXTEND study